This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.
|Articles|June 11, 2014
Adlens presents Adlens Sundials
Adlens recently introduced Adlens Sundials, featuring the same lens technology as the Adlens Adjustables but for sunglasses.
Advertisement
Oxford, England-Adlens recently introduced
Each lens is comprised of two wave-shaped plates that glide across one another to alter the power of each lens. The sunglasses feature dark lenses with UVA/UVB protection and can correct over 90 percent of spherical errors (lens power -6 to +3,5 dioptres). The four styles available include an all-black frame or black with temples available in pink, green, and blue.
Next:
Advertisement
Related to this article
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.
The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.
Nicole Haessly, OD, FAAO, discusses common unsafe contact lens habits, overlooked care steps, and how lens innovations have improved safety.
Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her performance vision evaluations.
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD.
Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Takeaways from this week in optometry: October 26-30
2
From our Editorial Board: Comments from the FDA Advisory Committee meeting on SYD-101
3
FDA designates OCT-980 as orphan drug for retinitis pigmentosa
4
First genotype-guided dry eye trial, PREDICT-1, completes randomization
5